How effective is selumetinib treatment and whether it can improve genetic diseases

Selumetinib is a selective MEK1/2 inhibitor that was first developed for the treatment of cancer. However, in recent years, its efficacy in the treatment of **the hereditary disease neurofibromatosis type 1 (NF1) ** has attracted widespread attention. NF1It is a common autosomal dominant genetic disease, and patients often suffer from symptoms such as neurofibromas, skeletal deformities, and learning disabilities. Selumetinib can inhibit the RAS/RAF/MEK/ERK signaling pathway and intervene in the abnormal cell proliferation related to NF1 mutations, thereby having a therapeutic effect on the disease.

In multiple clinical trials, selumetinib has shown a significant shrinkage effect on **NF1-related plexiform neurofibromas (PNs). The most representative one is a phase II clinical trial led by the NCI of the United States. The results show that about 70%of patients have reduced tumor volume by more than20% after using selumetinib, and tumor symptoms (such as pain, movement disorders) in some pediatric patients have been significantly improved. These results prompted the FDA to approve selumetinib in 2020 for the treatment of children aged 2 years and older with inoperable PNs.

It is worth noting that selumetinib cannot"radically cure" hereditary diseases such as NF1, but it can effectively control the progression of tumors, reduce symptoms, and improve quality of life, especially in patients with high surgical risks or unresectable tumors. It is one of the few drug treatment options currently. The course of treatment is usually lengthy, and side effects such as rash, gastrointestinal discomfort, and liver function abnormalities need to be closely monitored to ensure treatment safety.

To sum up, selumetinib has clear efficacy in improving NF1 related tumor burden and delaying disease progression. It is currently the only one approved by FDAOne of the targeted drugs approved for this rare genetic disease. With the deepening of research, selumetinib or its similar drugs may play a role in more genetic mutation-related diseases in the future, bringing new hope for the treatment of genetic diseases.

Reference materials:https://www.drugs.com/